

This is a resubmission of manuscript number MS ID#: JPET/2019/263699

**CANNABIDIOL ENHANCES INTESTINAL CB2 RECEPTOR EXPRESSION AND
ACTIVATION INCREASING REGULATORY T CELLS AND REDUCES MURINE ACUTE
GRAFT-VERSUS-HOST DISEASE WITHOUT INTERFERING WITH THE GRAFT-VERSUS-
LEUKEMIA RESPONSE**

Correspondent author: Marina Gomes Miranda e Castor Romero

Bárbara Betônico Berg^{1,2}, Jaqueline Silva Soares¹, Isabela Ribeiro Paiva^{1,2}, Barbara Maximino Rezende³, Milene Alvarenga Rachid⁴, Stéfany Bruno de Assis Cau^{1,2}, Thiago Roberto Lima Romero^{1,2}, Vanessa Pinho⁵, Mauro Martins Teixeira^{2,6}, Marina Gomes Miranda e Castor^{1,2}.

1- Departamento de Farmacologia-ICB/UFMG; 2- Programa de Pós-graduação em Fisiologia e Farmacologia da UFMG; 3-Departamento de Enfermagem Básica da Escola de Enfermagem da UFMG; 4- Departamento de Patologia Geral do Instituto de Ciências Biológicas da UFMG. 5 -Departamento de Morfologia - CPDF-ICB/UFMG; 6-Departamento de Bioquímica e Imunologia, CPDF-ICB/UFMG.

CBD ENHANCES TREG CELLS AND REDUCES GVHD BY CB2 ACTIVATION

Contact information: Dr. Marina Gomes Miranda e Castor Romero

E-mail: marinacastor@gmail.com

Permanent address: Universidade Federal de Minas Gerais, Instituto de Ciências Biológicas, Minas Gerais, Brazil. Laboratório de Farmacologia Cardiovascular e da Inflamação – LAFACI. A3 171. Telephone number: +55 31 3409-2709. Fax: +55 31 3409-2924.

Number of text pages: 18

Number of tables: 0

Number of figures: 8

Number of references: 53

Number of words in the Abstract: 216

Number of words in the Introduction: 518

Number of words in the Discussion: 1272

ABBREVIATIONS: ANOVA (analysis of variance); CB1 (cannabinoid receptor type 1); CB2 (cannabinoid receptor type 2); CBD (cannabidiol); CFU (colony forming units); ELISA (enzyme-linked immunosorbent assay); FACS (fluorescence activated cell sorting); GFP (green fluorescent protein); GVHD (graft-versus-host disease); GVT (Graft-versus-tumor); i.p. (intraperitoneal); i.v. (intravenous); IFN γ (interferon gamma); n (number of observations); PBS (Phosphate buffered saline); SD (standard deviation); TNF α (tumor necrosis factor alpha).

Section: Inflammation, Immunopharmacology, and Asthma

Abstract

Cannabidiol (CBD) is a highly lipidic phytocannabinoid with remarkable anti-inflammatory effects. The aim of this study was to evaluate CBD's effects and mechanisms of action in the treatment of mice subjected to acute graft-versus-host disease (aGVHD). aGVHD was induced by the transplantation of bone marrow cells and splenocytes from C57BL-6j to Balb-c mice. The recipient mice were treated daily with CBD, and the treatment reduced mouse mortality by decreasing inflammation and injury and promoting immune regulation in the jejunum, ileum, and liver. Analysis of the jejunum and ileum showed that CBD treatment reduced the levels of CCL2, CCL3, CCL5, TNF- α , and IFN- γ . CCL3 and IFN- γ levels were also decreased in the liver. Mechanistically, CBD also increased the number of CB₂ receptor on CD4⁺ and FoxP3⁺ cells in the intestine, which may explain the reduction in pro-inflammatory cytokines and chemokines. Antagonists of the CB₂ receptor reduced the survival rates of CBD-treated mice, suggesting the participation of this receptor in the effects of CBD. Furthermore, treatment with CBD did not interfere with the graft-versus-leukemia response. CBD treatment appears to protect aGVHD mice by anti-inflammatory and immunomodulatory effects, partially mediated by CB₂ receptor interaction. Altogether, our study suggests that CBD represents an interesting approach in the treatment of aGVHD, with potential therapeutic applications in patients undergoing bone marrow transplantation.

KEYWORDS: graft-versus-host disease, cannabidiol, cannabinoid receptor, Treg cells.

Significance Statement: This study provides for the first time a mechanism by which cannabidiol, a phytocannabinoid with no psychoactive effect, induces immunomodulation in the Graft-versus-host disease. Enhancing intestinal CB₂ receptor expression on CD4⁺ and Foxp3⁺ cells and increasing the number of these regulatory cells, cannabidiol decreases pro-inflammatory cytokines and increases

GVHD mice survival. This effect is dependent of CB2 receptor activation. Besides, cannabidiol did not interfere with Graft-versus-leukemia, a central response to avoid primary disease relapse.

Introduction

The main complication following allogeneic hematopoietic cell transplantation (alloHSCT) is graft-versus-host disease (GVHD), a systemic inflammatory condition, secondary to alloHSCT, that leads to significant morbidity and mortality in humans (Major-Monfried *et al.*, 2018). AlloHSCT is the transplantation of cells between two genetically non-identical individuals (Beatty *et al.*, 1995; Ljungman *et al.*, 2006) and is a curative therapy for several malignant and nonmalignant diseases, including leukemia (Gale, 1981), lymphoma (Curtis *et al.*, 1997; Hartmann *et al.*, 1997), thalassemia (Lucarelli *et al.*, 1990), aplastic anemia (Locasciulli *et al.*, 2007), and autoimmune diseases, such as lupus (Marmont, 1994; Gladstone *et al.*, 2017).

GVHD occurs because of histo-incompatibilities identified by T cells that react against host tissues causing extensive damage (Ho *et al.*, 2001). Classically, acute GVHD (aGVHD) occurs within 100 days after transplantation, and chronic GVHD after this period. However, nowadays, aGVHD is defined mainly by erythematous rash, gastrointestinal symptoms, cholestatic hepatitis, immune suppression, T cell infiltration, and tissue apoptosis (Zeng, 2018). The pathophysiology of aGVHD is complex and involves several inflammatory cytokines, whose release starts during the conditioning regimen (irradiation and/or chemotherapy), leading to a pro-inflammatory environment that promotes T cell activation, proliferation, and differentiation against target organs (Schroeder *et al.*, 2011). About 50% of patients with GVHD will die because of disease complications, and this is matched only by aGVHD's high incidence rate among patients who undergo alloHSCT (Barton-Burke *et al.*, 2008; Yang *et al.*, 2017). Although alloHSCT leads to a higher chance of developing aGVHD, it also provides a stronger graft-versus-tumor (GVT) reactivity, by which the new immune system recognizes and mediates the

immunological eradication of reminiscent cancer cells (Noriega *et al.*, 2015; van Bergen *et al.*, 2017). Therefore, GVT reactivity represents a strong plea in the recommendation of alloHSCT as a curative therapy for malignant conditions (Kolb, 2008).

The current treatment of aGVHD includes high doses of steroids, promoting host immune suppression but also leading to several adverse effects, such as reduced GVT reactivity, so new therapeutic approaches are urgently needed (Devetten *et al.*, 2004; Shlomchik, 2007; Devergie *et al.*, 2008; Poetker *et al.*, 2010; Peppas *et al.*, 2011; Jamil *et al.*, 2015). Meanwhile, cannabinoids emerge as strong pharmacological candidates for several pathologies, such as multiple sclerosis (Kozela *et al.*, 2011), colitis (Borrelli *et al.*, 2009), and inflammatory bowel disease (Schicho *et al.*, 2012), but their psychoactive effects restrict their widespread therapeutic use. Cannabidiol (CBD), an abundant phytocannabinoid of *Cannabis sativa*, with well-known anti-inflammatory effects, is not psychoactive (Häußermann *et al.*, 2017; Adams *et al.*, 2018) and is currently in a Phase II study for the treatment of GVHD in humans, with reports of benefits from CBD treatment, such as increased survival (Yeshurun *et al.*, 2015). Furthermore, although there have been attempts to identify CBD's mechanisms of action in murine models (Khuja *et al.*, 2019), several gaps remain regarding the alterations triggered by CBD in the host organism and immune system. Therefore, the aim of this study was to investigate how CBD treatment can lead to an increase in mouse survival and by what mechanisms it can modulate the immune response regarding murine aGVHD.

1. Methods

1.1. Animals

All the experiments were performed on eight-week-old male Balb-c mice, and the donor group consisted of eight-week-old male C57BL/6j mice from the Center of Bioterism, Federal University of Minas Gerais, Belo Horizonte, Brazil. The animals were housed under a 12-h light–dark cycle with food and

water available *ad libitum*. The animal procedures were approved by the Ethics Committee on Animal Experimentation of the Federal University of Minas Gerais (no. 337/2014) and were carried out according to the Guide for the Care and Use of Laboratory Animals. The mice were euthanized through cervical displacement.

The sample size was defined based on the sample variance of three different GVHD-induction experiments previously performed by our group (Castor et al., 2010; Castor et al., 2011; Castor et al., 2012). For the sample size, we used the following equation:

$$n = \left(\frac{\left[\frac{z\alpha}{2} * \sigma \right]}{e} \right)^2$$

where n represents the sample size, $z\alpha/2$ is the relative value from the z table, e is the absolute error, and σ is the standard deviation. To obtain a reliability of 95%, we needed a sample size of five mice per group for our experiments.

1.2. Disease induction

For bone marrow ablation, the mice were irradiated with 7 Gy of gamma radiation before transplantation and received 3×10^7 splenocytes and 1×10^7 bone marrow cells i.v., either from the C57BL/6j donor mice (and thus developed GVHD) or from the Balb-c donor (and thus did not develop GVHD); the mice receiving cells from the Balb-c donor were considered the control group. The cells were acquired according to Castor *et al.* (2010). The mice were randomly divided into the groups. After induction, the mice were monitored daily using a clinical standard scoring system consisting of seven points: hunching/posture, activity, fur texture, weight loss, skin integrity, diarrhea, and occult blood in the feces. The scoring was given according to the grade of clinical manifestation, with 0 = normal, 1 = minor alteration, 1.5 = moderate alteration, and 2 = severe alteration, as described previously (Castor *et al.*,

2010). To avoid animal suffering, we standardized 10 points as the cutoff point.

1.3. Drugs

The mice receiving C57BL/6j cells (allogeneic transplant) were treated either with CBD (THC-Pharm, Frankfurt, Germany, and STI-Pharm, Brentwood, UK) in doses of 10, 30, and 60 mg/kg or its vehicle (5% Tween80 in sterile PBS-1x). The participation of cannabinoid receptors was assessed by a treatment with AM251 (Tocris®) 1 mg/kg or AM630 (Tocris®) 1 mg/kg (35), being a CB1 and a CB2 antagonist, respectively. The vehicle of both these antagonists contained 2.5% DMSO in PBS-1x and CBD's vehicle. All drugs were administered by a daily intraperitoneal (i.p.) injection, starting on the day of disease induction and continuing for the duration of the protocols.

1.4. Histopathology

On day seven, the intestine and liver were fixed and stained with H&E. The entire extension of the jejunum and ileum walls and the liver were analyzed blindly by a fellow pathologist under an optical microscope (Olympus BX51, Tokyo, Japan). Numerical values were assigned to changes observed in each of the intestinal layers (the mucosa, lamina propria, muscular, and serosa layers). The epithelium was scored as follows: 0 = without alterations; 1 = reactive and aspecific alterations; 2 = erosion or loss of the architecture of the region of crypts or the surface of the epithelium; and 3 = nuclear changes and hyperplasia in the crypt or surface epithelium, with or without evidence of ulceration and loss of goblet cells. The other layers were scored as follows: 0 = normal aspect; 1 = discrete inflammatory cell infiltration; 2 = moderate inflammatory cell infiltration, swelling, and congestion; 3 = severe inflammatory infiltration and villous enlargement with swelling and congestion in the lamina propria; and 4 = ischemic necrosis and intense inflammatory alterations in the muscular and serosa layers. Each animal received a total score generated by the summation of the three individual scores (maximum index 9). In the liver, there were degenerative alterations in the parenchyma, and a numerical value was

assigned to the changes observed: 0 = normal; 1 = discrete cytoplasmatic vacuolization and focal eosinophilia; 2 = diffuse vacuolization, alterations in hepatocyte form, and moderate nucleus alterations; and 3 = hepatocyte necrosis and diffuse vacuolization, alterations in hepatocyte form, and accentuated nucleus alterations. Inflammatory infiltration of the liver was scored as follows: 0 = none or rare, 1 = discrete presence of infiltrates in the periportal area, 2 = discrete or moderate presence of infiltrates in the periportal and intralobular areas, and 3 = accentuated presence of infiltrates in the periportal and intralobular areas. Each animal received a total score generated by the summation of the two individual scores (maximum index 6).

1.5. Bacterial translocation

Intraperitoneal wash was performed on the seventh day. The mice were anesthetized with 80 μ l of ketamine/xylazine (2:1), and the washing was performed with 1 mL of a sterile solution of PBS 1x. The wash was incubated overnight in a Müller–Hilton agar medium at 37 °C, and the number of colony-forming units (CFUs) was counted. The mean values of the CFUs are shown.

1.6. ELISA

On the seventh day, the mice were euthanized, and 100 mg of the intestine and liver were collected for the ELISA assay. The samples were then processed following the manufacturer's instructions (R&D System) and were read in a wavelength of 490 nm in a spectrophotometer, and the absorbance value was determined for each sample. We evaluated CCL2, CCL3, CCL5, TNF α , and IFN γ .

1.7. Flow cytometry

Seven days after disease induction, the intestine, spleen, liver, and bone marrow were collected and processed as previously described (Resende *et al.*, 2017). Cells were counted, and a total of 1×10^6 cells were stained with the following antibodies: CD3 (Pacific Blue [RRID-17-A2], BioLegend), CD4 (PE-

Cy7 [RRID-RM45], BioLegend), CD8 (FITC [RRID-53-6.7], BioLegend), CD25 (APC [RRID-PC61], BioLegend), and CD28 (PE-A [RRID-37.51], BioLegend). For cell surface markers, we used FoxP3 (PE-A [RRID-MF14], BioLegend); H2D^b (Alexa Fluor-647 [RRID-KH95], BioLegend); and H2D^d (PE [RRID-34212], BioLegend) were used for the bone marrow to evaluate chimerization. A total of 100,000 events were considered in the FACS analysis for each sample, and the cells were acquired with a BD FACSCanto II cytometer and analyzed using FlowJo V10 software (BD Immunocytometry Systems, San Jose, CA, USA).

2.8 Immunofluorescence

At day 7 after transplant intestinal slices were processed to immunofluorescence assay. The antibody to CD4, CD8, FoxP3 and cannabinoid receptor 2 (CB2), described on supplemental material (Supp. Fig. 1), were used to investigate the presence of CB2 on these cells and if cannabidiol treatment can induce CB2 expression on them. The Nuclei were marked with 4,6-diamidino-2-phenylindole (Life Technology, DAPI/D1306-Carlsbad). Slides were mounted using 60% glycerol. Zen microscope was used to acquire images with suitable filters, for selectively detecting the fluorescence of FITC (green), AlexaFluor 488 (green), AlexaFluor 594 (red), PE (red), or DAPI (blue) (Gonzaga, Campolina-Silva et al. 2017). For each tissue section, ten regions were randomly captured, by an independent experiment-blinded user, at 100× magnification, totaling fifty pictures per group (n=5). Images were analyzed using ImageJ software v 1.53c 1.41 (National Institutes of Health, USA, public domain).

1.8. Graft-versus-tumor response

On the day of GVHD induction, after radiation, the mice received murine mastocytoma P815⁺ cells i.v. (H-2d, American Type Culture Collection, Rockville, MD—RRID TIB-64) transduced with an EF1aGFP vector (National Institute of Cancer, Rio de Janeiro, Brazil) in a concentration of 5 x 10⁴ cells. The mice

were treated with a vehicle or CBD for seven days. The spleen and lymph nodes (mesenteric and inguinal) were separately processed in the FACS analysis by Flow Cytometry (FacsScaibur). The number of tumor cells was evaluated by the percentage of GFP⁺ fluorescence.

1.9. Statistical analysis

Statistical analysis was performed with GraphPad Prism 8.0.2 software. Normality was tested by the Shapiro–Wilk test, and outliers were identified by the Grubbs test ($\alpha = 0.05$). The samples were tested by one-way ANOVA followed by Fisher’s LSD *post hoc* test to address differences between groups. In the survival curves, the differences were assessed by the log-rank (Mantel–Cox) test. Samples were considered different when $p < 0.05$.

2. Results

2.1. Engraftment and mouse survival

MHC disparities between animals led to the development of GVHD (Figure 1 A). The most effective dose of CBD was chosen by a daily treatment with 10, 30, or 60 mg/kg. Survival was assessed daily (Figure 1 B). We found no difference between CBD 10 mg/kg and the vehicle. Regarding the other doses, the CBD 30 mg/kg group displayed the highest survival (80%), with the CBD 60 mg/kg group showing a survival rate of 40%. CBD 30 mg/kg was clearly the most effective dose when compared with CBD 10 mg/kg ($p = 0.0127$), but there was no statistically significant difference between CBD 30 mg/kg and CBD 60 mg/kg ($p = 0.2207$). The clinical parameters of the mice were evaluated for 20 days and translated into a score (Figure 1 C). In this way, a dose of 30 mg/kg was chosen to be used for the next experimental procedures. During our experiments, the CBD 30 mg/kg group displayed a variation from 60% to 80% in survival, and the mortality in the vehicle group varied from 12 to 18 days.

Furthermore, the bone marrow samples collected seven days after disease induction revealed that the

CBD 30 mg/kg treatment did not interfere with engraftment, as assessed by the percentages of the histocompatibility antigens H2D^b and H2D^d in the CBD and vehicle groups. The vehicle group presented 75% of H2D^b, and the mice treated with CBD presented 69% of H2D^b (Figure 1D).

2.2. Cellular recruitment, activation, and damage

The spleen, intestine, and liver were collected for analysis. Flow cytometry of the spleen (Supp. Fig. 2) revealed no difference in the total number of lymphocytes (Figure 2 A) or in the number of CD8⁺ cells among the groups (Figure 2 C). Additionally, we found an increased number of CD4⁺ cells in the vehicle group when compared with the control group, but there was no difference between the CBD and the vehicle group in this respect (Figure 2 B). Moreover, we found no difference in the activation of CD4⁺ cells (Figure 2 D), but CD8⁺ cells were found to be increased in the vehicle group when compared with the control group. This profile was not altered by CBD treatment (Figure 2 E), and the number of CD4⁺, CD25⁺, and FoxP3⁺ cells, collectively known as Tregs, was not different between the groups (Figure 2 F).

The H&E slices of the small intestine revealed that CBD treatment reduced damage to the tissue, preserving intestinal crypts, reducing inflammatory infiltration, preventing edema, and improving the general tissue score when compared with the vehicle group (Figure 3 A-D). Supportive of this improvement in the small intestine, intraperitoneal washing also revealed that while mice from the vehicle group, as compared with the control group, had an increased number of CFUs translocating to the peritoneal cavity, CBD treatment prevented translocation, protecting the intestinal barriers (Figure 3 E).

Flow cytometry of the small intestine (Supp. Fig. 3) revealed an increased number of total lymphocytes in the CBD group in comparison with the vehicle group; however, the vehicle group had not an increased number of total lymphocytes in comparison with the control group (Figure 4 A).

Both CD4⁺ cells (Figure 4 B) and CD8⁺ cells (Figure 4 C) were increased in the CBD group when compared with the vehicle group, but there was no difference between the vehicle and the control group. Interestingly, there was no difference in the activation of CD4⁺ cells between the CBD and the vehicle group, but in the latter group, the activation of CD4⁺ cells was increased in comparison with the control group (Figure 4 D). As for CD8⁺ cells, the vehicle group revealed an increase in activation when compared with the control group, and CBD did not prevent this activation (Figure 4E). Interestingly, the CBD group displayed a higher number of Tregs when compared with the vehicle group, and the latter group showed no difference from the control group in this respect (Figure 4 F). Next, at the same time point, we verified the cytokine and chemokine profiles of the mice. The vehicle group displayed an increase in CCL2, CCL3, TNF- α , IFN- γ , and IL-10, while CBD, surprisingly, led to a reduction in CCL2, CCL3, CCL5, TNF- α , IFN- γ , and IL-10 in the intestine (Figure 4 G-L).

The same parameters were evaluated in the mice's liver seven days after disease induction. Liver slices stained with H&E showed that CBD, as compared with the vehicle, was able to reduce inflammatory infiltration in the periportal and intralobular regions near the centrilobular veins of the liver (Figure 5 A-D). In addition, ELISA, in the liver, showed that CBD decreased the levels of CCL2, CCL3, and IFN- γ (Figure 5 E, F, and I). Flow cytometry of the liver (Supp. Fig. 4) revealed an increased number of lymphocytes in the CBD group when compared with the vehicle group (Figure 5 K), and this was also the case for CD4⁺ cells (Figure 5 L). However, we found no difference in CD8⁺ cells among the groups (Figure 5 M). Nevertheless, when activation was assessed by CD28⁺ staining, the CD4⁺ cells were found to be increased in the vehicle group when compared with the control group, while in the CBD group the activation was higher than in the vehicle group (Figure 5 N). The CD8⁺ cells presented the same low level of activation in all groups (Figure 5 O). Moreover, in the liver, the CBD group did not display a difference in the number of Treg cells when compared with the vehicle group, and neither did the vehicle

group when compared with the control group (Figure 5 P).

2.3. Graft-versus-leukemia response

The mice received P815GFP⁺ mastocytoma cells on the day of disease induction. After seven days, the response was assessed by flow cytometry. The control group received only tumor cells and a syngeneic transplant. In this group, we observed an increase in P815GFP⁺ cells in the spleen and lymph nodes, indicating tumor growth (Figure 6 A and B). The vehicle group received tumor cells and allogeneic bone marrow and splenocytes, leading to a reduction in the number of GFP⁺ tumor cells compared with the control group (Figure 6 A and B). In the same way, CBD treatment did not interfere with the allograft response against tumor cells (P815GFP⁺), as the presence of tumor cells was severely reduced in the spleen (Figure 6 A) and lymph nodes (Figure 6 B) of the mice that received CBD, as compared with the mice in the control group, preserving the graft-versus-tumor response.

2.4. CBD's effect is dependent on the CB2 receptor

The mice were treated with CBD, CBD + AM630, CBD + AM251 or AM630, and AM251 alone, with AM630 being a selective antagonist of the CB2 receptor and AM251 a selective antagonist of the CB1 receptor, and the survival of the mice was assessed. Interestingly, the mice that received AM251 with CBD survived, as did the mice from the CBD group (Figure 7 A). Furthermore, both the vehicle group and the vehicle CBD + vehicle antagonist group were different from the control group ($p < 0.001$). The CBD group was different from its vehicle ($p = 0.0043$) but was not different from the CBD + AM251 group, and this last group was different from the vehicle CBD + vehicle antagonist group ($p = 0.0054$).

Surprisingly, we found that the mice treated with AM630 together with CBD exhibited a lower survival rate than the mice treated with CBD alone (Figure 7 B). Moreover, the vehicle group's survival was significantly different from the control group's ($p < 0.001$); the same was found when the control group

was compared with the vehicle CBD + vehicle AM630 group ($p < 0.001$). There was no difference between the vehicle CBD + vehicle AM630 group and the CBD + AM630 group. Finally, the CBD + AM630 group was different from the CBD group ($p = 0.034$). Additionally, the mice treated with either AM251 (Figure 7 C) or AM630 (Figure 7 D) were not different from their respective vehicle groups and did not display the same increase in survival as the mice that received CBD treatment.

To verify CB2 receptor expression in the target organs we performed an immunofluorescence assay in the intestine, major target organ of GVHD. CB2 expression is not altered by GVHD induction. However, CBD treatment increase CB2 receptor expression in the intestinal cells (Figure 7 E). As FACS analysis, immunofluorescence showed an increased number of CD4⁺ cells in the CBD group compared to GVHD and Control group (Figure 7 E). Positive colocalization of CD4 and CB2 staining was increased in CBD group, in comparison both to control and GVHD groups (Figure 7 E and Supp. Fig. 5). This result was also found regarding FoxP3 with CB2 staining (Figure 7 F and Supp. Fig. 6). However, although CD8 was also increased in CBD when compared to the other groups, CB2 receptor expression was found to be increased only in comparison to control and not GVHD group ($p = 0.1232$) and there was no difference between CBD and GVHD groups remarking colocalization (Fig 7 G and Supp. Fig. 7). Pearson's coefficient was found to be mainly positive in CD4/CB2 analysis (Control 0.197 ± 0.127 ; GVHD 0.161 ± 0.103 ; CBD 0.333 ± 0.143 ; with no difference between groups); CD8/CB2 analysis (Control -0.0393 ± 0.169 ; GVHD 0.275 ± 0.162 ; CBD 0.253 ± 0.311 ; with no difference between groups); and regarding FoxP3 (Control 0.119 ± 0.075 ; GVHD 0.179 ± 0.081 ; CBD 0.233 ± 0.081 ; with statistical difference between control and CBD $p = 0.0418$).

3. Discussion and conclusions

First, we evaluated three different doses of CBD (10, 30, and 60 mg/kg), based on the published literature (De Filippis *et al.*, 2011; Campos *et al.*, 2015; Vilela *et al.*, 2015; Ahmed *et al.*, 2016), to determine the

most appropriate dose for the treatment of aGVHD. The mice treated with CBD 30 mg/kg, however, were not free from the disease, as assessed by the clinical score, and displayed a reduced disease progression and mortality when compared with the vehicle group. Not only that, but when chimerism was assessed, CBD did not affect bone marrow engraftment, as the animals recovered to display the same percentage of bone marrow cells as the animals in the vehicle group, which was verified both in the bone marrow itself and in the spleen, a secondary lymphoid organ.

The absence of a functional immune system would have left the mice susceptible to opportunistic diseases and is proved to be of the highest importance when considering possible treatments for GVHD in humans (Jamil *et al.*, 2015; Admiraal *et al.*, 2017). Therefore, in the present study, the presence of active and proliferating T cells in the spleen reinforces that CBD does not lead to an immunosuppressive status, as it does not lead to a reduction in T CD4⁺ and CD8⁺ cells when compared with the vehicle group. Jamil *et al.* (2015) highlighted the importance of not entirely suppressing GVHD because it is related to a higher GVT response, which will protect the recipient from reminiscent tumor cells. The presence of transplanted cells in secondary lymphoid organs is important for the protective effect of the GVT response; however, it also relates to aGVHD development (Tkachev *et al.*, 2018). In our study, CBD treatment was able to protect target organs against damage without interfering with the GVT response. These first two results are of the utmost importance when considering CBD usage in both prevention and treatment for patients who undergo alloHSCT.

CD4⁺ cells are responsible for generating both thymic-derived and inducible Tregs (Ferrara *et al.*, 2017). Tregs are characterized by the presence of CD4⁺, CD25⁺, and FoxP3⁺ markers and promote tolerability, suppressing alloreactive lymphocytes. This regulation is key to aGVHD suppression/reduction (Blazar *et al.*, 2012). Like our findings, the results reported by Edinger *et al.* (2003) of an experimental model of Treg transfer showed that, even though Tregs are able to reduce aGVHD, they did not affect the GVT

response, probably because of cytolytic effector T cells, especially CD8⁺ cells in the lymphoid organs (Schneidawind *et al.*, 2013). CD8⁺ cells or T cytotoxic cells are vital to anti-tumoral immunological responses (Uri *et al.*, 2018). In this regard, we attested that CBD treatment does not reduce the migration of CD4⁺ or CD8⁺ cells to lymphoid and target organs. In our study, the main organ evaluated was the intestine, which is a major target organ of aGVHD and is regarded as one of the main environments for antigen presentation, acting as a barrier against commensal microbiota (Peled *et al.*, 2016). CBD protected the intestinal barriers by preventing the migration of bacteria into the peritoneal cavity, while in the vehicle group, the intestinal barrier was inefficient in preventing this translocation; owing to intestinal damage, bacteria were found in the peritoneal cavity (Figure 3 E).

In the intestine, CBD led to an increase in CD4⁺ and CD8⁺ populations, although there was no increase in the activation status of these cells. Another important difference between CBD and the vehicle is that CBD promotes Treg cells in the intestine, a factor that may elucidate the reduction in intestinal damage and the level of pro-inflammatory cytokines (TNF- α and IFN- γ) and chemokines (CCL2, CCL3, and CCL5). The chemokines CCL2, CCL3 and CCL5 are mandatory for recruitment of inflammatory cells to the target organs (Castor *et al.*, 2010; Blazar *et al.*, 2012 and Ferrara *et al.*, 2017). In this way, we have investigated if the recruitment process was impaired in CBD treated mice. Using an intravital assay, the rolling and adhesion of inflammatory cells on intestinal microvasculature was examined. There was no difference between vehicle and CBD treated mice (Supp. Fig. 8).

Based on the findings by Panoskaltsis-Mortari *et al.* (2004), effector cells migrate first to the intestine and later to the liver. We hypothesize that CD4⁺ activation and the further differentiation of CD4⁺ cells into FoxP3⁺ cells would also occur later in the liver and that, therefore, the number of CD4⁺ cells were not increased on the seventh day of the disease in vehicle. The timing of the disease in the liver explains why we found that CCL2, CCL3, and IFN γ were increased only in the vehicle group; interestingly, this

increase was prevented by CBD. Tregs have been described to suppress cytokine production of both CD4⁺ and CD8⁺ effector cells (Helling *et al.*, 2015), a process that elucidates our findings regarding the ELISA assay in the intestine. Additionally, the presence of Tregs is necessary for the promotion of immune tolerance, preventing an overwhelming graft immune response after alloHSCT (Becker *et al.*, 2007; Beres *et al.*, 2013). To our knowledge, this is the first time that CBD has been shown to increase CD4⁺, CD25⁺, and FoxP3⁺ cells in an experimental model of aGVHD, an effect that elucidates part of the modulatory mechanism of the inflammatory response and the increase in mouse survival and organ protection.

Another interesting mechanism of CBD is that, in our model, the CB2 but not the CB1 receptor is partially responsible for mouse survival, and we believe that it may also be responsible for the immunomodulatory effects of CBD. Both receptors are classified as cannabinoid receptors, as they are sensitive to both endogenous cannabinoids and some phytocannabinoids; however, they unleash different effects in the host organism. The CB1 receptor is present mainly in the central nervous system, while the CB2 receptor is more abundant in the peripheral nervous system and immune cells (Adams *et al.*, 2018). The presence of CB2 in immune cells is correlated with its modulatory effects, including cytokine inhibition and reduction in antigenic presentation (Ehrhart *et al.*, 2005; Horvath *et al.*, 2012). CB2 receptor is expressed on nearly all immune cells and its absence on donor CD4⁺ or CD8⁺ T cells, or administration of a selective CB2 pharmacological antagonist, exacerbated acute GVHD lethality (Yuan, Belle *et al.* 2020). CBD has about 74% higher affinity for CB2 than for CB1 (Rosenthaler *et al.*, 2014). In this way, we investigate the effect of CBD on CB2 receptor expression on intestine. CBD treatment was able to induce an increase of CB2 receptor expression on CD4⁺ and FoxP3⁺ cells in the intestine of mice subject to GVHD. The correlation between CD4 and CB2, but also of FoxP3 and CB2 further reinforces our hypothesis that cannabidiol might stimulates FoxP3 differentiation by interaction with CB2 receptor.

These findings reinforce CB2 role in regulation of GVHD and suggests an interesting pharmacological therapeutic targeting.

In the present study, the effects of CBD may be associated with CB2 activation. However, it is important to highlight that CBD can exert different effects upon a vast number of different receptors (Pertwee, 2006) and that, therefore, additional mechanisms may underlie the full modulatory effects of CBD. Lastly, in our model of aGVHD, CBD treatment was able to increase survival and reduce the damage of target organs. The increase of CB2 receptor in the intestine leads to an immunoregulatory environment with an enhanced number of Treg cells and a reduction in the major GVHD pro-inflammatory mediators. Moreover, CBD increase the number of CD8⁺ cells maintaining the GVL effect. Therefore, it may be concluded that CBD represents an interesting approach in the treatment of aGVHD (Figure 8).

Acknowledgments

We would like to thank Prof. Aline C. Campos of the Escola de Medicina de Ribeirão Preto, Departamento de Farmacologia-USP, for providing the cannabidiol for our experiments.

Conflict of interest statement

The authors declare no conflict of interest in this study.

Author Contribution

Participated in research design: Berg, Castor, Pinho, Teixeira and Romero.

Conducted experiments: Berg, Soares, Paiva and Castor.

Contributed new reagents or analytic tools: Pinho, Teixeira, Rezende, Cau and Romero.

Performed data analysis: Berg, Soares, Rezende, Rachid and Castor.

Wrote or contributed to the writing of the manuscript: Berg, Castor, Pinho and Teixeira.

All authors revised the manuscript and approved the final version.

References

- Adams J, Unett D, Anthony T, Gatlin J, Gaidarov I (2018). APD371: a potent, highly selective, full agonist of the human CB2 receptor with sustained analgesic effects in rodents. *The Journal of Pain* **19**(3): S2.
- Admiraal R, de Koning CC, Lindemans CA, Bierings MB, Wensing AM, Versluys AB, *et al.* (2017). Viral reactivations and associated outcomes in the context of immune reconstitution after pediatric hematopoietic cell transplantation. *Journal of Allergy and Clinical Immunology* **140**(6): 1643-1650. e1649.
- Ahmed W, Katz S (2016). Therapeutic Use of Cannabis in Inflammatory Bowel Disease. *Gastroenterology & hepatology* **12**(11): 668-679.
- Barton-Burke M, Dwinell DM, Kafkas L, Lavalley C, Sands H, Proctor C, *et al.* (2008). Graft-versus-host disease: a complex long-term side effect of hematopoietic stem cell transplant. *Oncology* **22**(11 Suppl Nurse Ed): 31-45.
- Beatty PG, Mori M, Milford E (1995). Impact of racial genetic polymorphism on the probability of finding an HLA-matched donor. *Transplantation* **60**(8): 778-783.
- Becker C, Kubach J, Wijdenes J, Knop J, Jonuleit H (2007). CD4-mediated functional activation of human CD4+CD25+ regulatory T cells. *European journal of immunology* **37**(5): 1217-1223.
- Beres AJ, Drobyski WR (2013). The role of regulatory T cells in the biology of graft versus host disease. *Frontiers in immunology* **4**: 163.
- Blazar BR, Murphy WJ, Abedi M (2012). Advances in graft-versus-host disease biology and therapy. *Nature reviews. Immunology* **12**(6): 443-458.
- Borrelli F, Aviello G, Romano B, Orlando P, Capasso R, Maiello F, *et al.* (2009). Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant *Cannabis sativa*, is protective in a murine model of colitis. *Journal of molecular medicine* **87**(11): 1111-1121.
- Campos AC, Brant F, Miranda AS, Machado FS, Teixeira AL (2015). Cannabidiol increases survival and promotes rescue of cognitive function in a murine model of cerebral malaria. *Neuroscience* **289**: 166-180.
- Castor MG, Rezende B, Resende CB, Alessandri AL, Fagundes CT, Sousa LP, *et al.* (2010). The CCL3/macrophage inflammatory protein-1 α -binding protein evasin-1 protects from graft-versus-host disease but does not modify graft-versus-leukemia in mice. *Journal of immunology* **184**(5): 2646-2654.
- Curtis RE, Rowlings PA, Deeg HJ, Shriner DA, Socié G, Travis LB, *et al.* (1997). Solid cancers after bone marrow transplantation. *New England Journal of Medicine* **336**(13): 897-904.
- De Filippis D, Esposito G, Cirillo C, Cipriano M, De Winter BY, Scuderi C, *et al.* (2011). Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis. *PLoS One* **6**(12): e28159.
- Devergie A, Janin A (2008). Graft versus host disease. *EBMT-ESH handbook*: 218-234.
- Devetten MP, Vose JM (2004). Graft-versus-host disease: how to translate new insights into new therapeutic strategies. *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation* **10**(12): 815-825.
- Edinger M, Hoffmann P, Ermann J, Drago K, Fathman CG, Strober S, *et al.* (2003). CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. *Nature medicine* **9**(9): 1144-1150.

Ehrhart J, Obregon D, Mori T, Hou H, Sun N, Bai Y, *et al.* (2005). Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. *Journal of neuroinflammation* **2**: 29.

Ferrara JL, Smith CM, Sheets J, Reddy P, Serody JS (2017). Altered homeostatic regulation of innate and adaptive immunity in lower gastrointestinal tract GVHD pathogenesis. *The Journal of clinical investigation* **127**(7): 2441-2451.

Gale R (1981). Bone marrow transplantation in leukemia. *Annals of clinical research* **13**(4-5): 367-372.

Gladstone DE, Petri M, Bolanos-Meade J, Dezern AE, Jones RJ, Fine D, *et al.* (2017). Long-term systemic lupus erythematosus disease control after allogeneic bone marrow transplantation. *Lupus* **26**(7): 773-776.

Hartmann O, Le Corroller AG, Blaise D, Michon J, Philip I, Norol F, *et al.* (1997). Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs: a randomized, controlled trial. *Annals of internal medicine* **126**(8): 600-607.

Häußermann K, Wagner U (2017). Cannabidiol: the rising star among the cannabinoids? *PHARMAKON* **5**(2): 123-128.

Helling B, König M, Dalen B, Engling A, Kromer W, Heim K, *et al.* (2015). A specific CD4 epitope bound by tregalizumab mediates activation of regulatory T cells by a unique signaling pathway. *Immunology and cell biology* **93**(4): 396-405.

Ho VT, Soiffer RJ (2001). The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. *Blood* **98**(12): 3192-3204.

Horvath B, Magid L, Mukhopadhyay P, Batkai S, Rajesh M, Park O, *et al.* (2012). A new cannabinoid CB2 receptor agonist HU-910 attenuates oxidative stress, inflammation and cell death associated with hepatic ischaemia/reperfusion injury. *British journal of pharmacology* **165**(8): 2462-2478.

Jamil MO, Mineishi S (2015). State-of-the-art acute and chronic GVHD treatment. *International journal of hematology* **101**(5): 452-466.

Khuja I, Yekhtin Z, Or R, Almogi-Hazan O (2019). Cannabinoids Reduce Inflammation but Inhibit Lymphocyte Recovery in Murine Models of Bone Marrow Transplantation. *International journal of molecular sciences* **20**(3): 668.

Kolb H-J (2008). Graft-versus-leukemia effects of transplantation and donor lymphocytes. *Blood* **112**(12): 4371-4383.

Kozela E, Lev N, Kaushansky N, Eilam R, Rimmerman N, Levy R, *et al.* (2011). Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C57BL/6 mice. *British journal of pharmacology* **163**(7): 1507-1519.

Ljungman P, Urbano-Ispizua A, Cavazzana-Calvo M, Demirer T, Dini G, Einsele Hf, *et al.* (2006). Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe. *Bone marrow transplantation* **37**(5): 439.

Locasciulli A, Oneto R, Bacigalupo A, Socié G, Korthof E, Bekassy A, *et al.* (2007). Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation. *Haematologica* **92**(1): 11-18.

Lucarelli G, Galimberti M, Polchi P, Angelucci E, Baronciani D, Giardini C, *et al.* (1990). Bone marrow transplantation in patients with thalassemia. *New England Journal of Medicine* **322**(7): 417-421.

Major-Monfried H, Renteria AS, Pawarode A, Reddy P, Ayuk F, Holler E, *et al.* (2018). MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD. *Blood* **131**(25): 2846-2855.

Marmont AM (1994). Immune ablation followed by allogeneic or autologous bone marrow transplantation: a new treatment for severe autoimmune diseases? *Stem Cells* **12**(1): 125-135.

Noriega V, Martínez-Laperche C, Buces E, Pion M, Sánchez-Hernández N, Martín-Antonio B, *et al.* (2015). The genotype of the donor for the (GT) n polymorphism in the promoter/enhancer of FOXP3 is associated with the development of severe acute GVHD but does not affect the GVL effect after myeloablative HLA-identical allogeneic stem cell transplantation. *PLoS one* **10**(10): e0140454.

Panoskaltis-Mortari A, Price A, Hermanson JR, Taras E, Lees C, Serody JS, *et al.* (2004). In vivo imaging of graft-versus-host-disease in mice. *Blood* **103**(9): 3590-3598.

Peled JU, Hanash AM, Jenq RR (2016). Role of the intestinal mucosa in acute gastrointestinal GVHD. *Hematology. American Society of Hematology. Education Program* **2016**(1): 119-127.

Peppas M, Krania M, Raptis SA (2011). Hypertension and other morbidities with Cushing's syndrome associated with corticosteroids: a review. *Integrated blood pressure control* **4**: 7-16.

Pertwee RG (2006). The pharmacology of cannabinoid receptors and their ligands: an overview. *International journal of obesity* **30** Suppl 1: S13-18.

Poetker DM, Reh DD (2010). A comprehensive review of the adverse effects of systemic corticosteroids. *Otolaryngologic clinics of North America* **43**(4): 753-768.

Resende CB, Rezende BM, Bernardes PT, Teixeira GM, Teixeira MM, Pinho V, *et al.* (2017). Alemtuzumab as graft-versus-host disease (GVHD) prophylaxis strategy in a developing country: lower rate of acute GVHD, increased risk of cytomegalovirus reactivation. *Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas* **50**(2): e5566.

Rosenthaler S, Pohn B, Kolmanz C, Huu CN, Krewenka C, Huber A, *et al.* (2014). Differences in receptor binding affinity of several phytocannabinoids do not explain their effects on neural cell cultures. *Neurotoxicology and teratology* **46**: 49-56.

Schicho R, Storr M (2012). A potential role for GPR55 in gastrointestinal functions. *Current opinion in pharmacology* **12**(6): 653-658.

Schneidawind D, Pierini A, Negrin RS (2013). Regulatory T cells and natural killer T cells for modulation of GVHD following allogeneic hematopoietic cell transplantation. *Blood* **122**(18): 3116-3121.

Schroeder MA, DiPersio JF (2011). Mouse models of graft-versus-host disease: advances and limitations. *Disease models & mechanisms* **4**(3): 318-333.

Shlomchik WD (2007). Graft-versus-host disease. *Nature reviews. Immunology* **7**(5): 340-352.

Tkachev V, Furlan SN, Potter EL, Zheng BH, Hunt DJ, Colonna L, *et al.* (2018). Delineating tissue-specific alloimmunity during acute GVHD: Am Assoc Immunol.

Uri A, Luhder F, Kerkau T, Beyersdorf N (2018). During acute graft versus host disease CD28 deletion in donor CD8(+) , but not CD4(+) , T cells maintain antileukemia responses in mice. *European journal of immunology* **48**(12): 2055-2067.

van Bergen CA, van Luxemburg-Heijs SA, de Wreede LC, Eefting M, Peter A, van Balen P, *et al.* (2017). Selective graft-versus-leukemia depends on magnitude and diversity of the alloreactive T cell response. *The Journal of clinical investigation* **127**(2): 517-529.

Vilela LR, Gomides LF, David BA, Antunes MM, Diniz AB, Moreira Fde A, *et al.* (2015). Cannabidiol rescues acute hepatic toxicity and seizure induced by cocaine. *Mediators of inflammation* **2015**: 523418.

Yang F, Lu D, Hu Y, Huang X, Huang H, Chen J, *et al.* (2017). Risk Factors for Graft-Versus-Host Disease After Transplantation of Hematopoietic Stem Cells from Unrelated Donors in the China Marrow Donor Program. *Annals of transplantation* **22**: 384-401.

Yeshurun M, Shpilberg O, Herscovici C, Shargian L, Dreyer J, Peck A, *et al.* (2015). Cannabidiol for the Prevention of Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation: Results of a Phase II Study. *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation* **21**(10): 1770-1775.

Zeng D (2018). Newly found arsons ignite the fire of gut GVHD. *The Journal of clinical investigation* **128**(3): 897-899.

Footnotes

The work was supported by grants from Coordenação de Aperfeiçoamento de Pessoal do Ensino Superior (CAPES); Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPQ) 444992-2014/6, Fundação de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG) APQ-01307-14 and Pró-Reitoria de Pesquisa da UFMG (PRPq) 307-05/2016.

Previously Presentations in Congress: This work was previously presented in the following scientific meetings: 4th International Symposium on Inflammatory Diseases (INFLAMMA IV), International Congress In Cannabinoid Medicine (CannX), XXVI Encontro de Pesquisa em Fisiologia & Farmacologia; Brazilian Congress of Pharmacology and Experimental Therapeutics (SBFTE) and The 5th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM); being rewarded in the last two.

Reprint requests: Marina Gomes Miranda e Castor Romero. Universidade Federal de Minas Gerais, Instituto de Ciências Biológicas, Minas Gerais, Brazil. 31270-901; Laboratório de Farmacologia Cardiovascular e da Inflamação – LAFACI. A3 171. Telephone number: +55 31 3409-2709.

Figure legends

Figure 1. Clinical aspects of experimental aGVHD. (A) Allogeneic transplant was performed from C57BL/6j mice with H2D^b phenotype to Balb-c mice with H2D^d phenotype. (B) Mice were treated with CBD 10mg/kg, CBD 30 mg/kg or vehicle and their survival was assessed daily. (C) Daily assessment of mice through clinical score. (D) Bone marrow engraftment was verified in vehicle and CBD 30mg/kg, seven days after the transplant, through flow cytometry. * indicates P<0.05 when compared to control group and # indicates P<0.05 when compared to the vehicle. Data were expressed in dispersion with mean and statistical difference was determined by Test t Student for engraftment and Log-rank (Mantel-Cox) test for survival. n=5 for all groups

Figure 2 - Flow Cytometry of mice spleen seven days after disease induction. (A) Total lymphocytes; (B) CD3⁺CD4⁺ cells; (C) CD3⁺CD8⁺ cells; (D) CD3⁺CD4⁺CD28⁺; (E) CD3⁺CD8⁺CD28⁺ and (F) CD4⁺CD25⁺FoxP3⁺. * indicates P<0.05 when compared to control group and # when P<0.05 when compared to vehicle. Data were expressed in dispersion with mean and statistical difference was determined by ANOVA with Fisher's LSD LSD *post hoc*. n=5 for all groups

Figure 3 - Intestines stained with H&E, (A) control, (B) vehicle and (C) CBD, in with stars represent edema, the dashed circle represents intestinal crypt and arrows point to mononuclear infiltrate. (D) Quantification of the histopathological score; the preservation of the intestine morphology is translated in (E) reduced bacteria translocation. Data were expressed in dispersion with mean and statistical difference was determined by ANOVA with Fisher's LSD LSD *post hoc*; n=5 for all groups.

Figure 4 – Flow Cytometry and ELISA of mice small intestines seven days after disease induction. (A) Total lymphocytes; (B) CD3⁺CD4⁺ cells n=5/5/5; (C) CD3⁺CD8⁺ cells n=5/5/5; (D) CD3⁺CD4⁺CD28⁺ n=5/5/4; (E) CD3⁺CD8⁺CD28⁺ n=5/5/4 and (F) CD4⁺CD25⁺FoxP3⁺ n=5/5/5 cells; (G) CCL2, (H) CCL3, (I) CCL5, (J) TNF α , (K) IFN γ and (L) IL-10. Data was represented in dispersion graphs with

mean; n=5 for all groups, except when specified. * indicates $P < 0.05$ when compared to control group and # when $P < 0.05$ when compared to vehicle. Data were expressed in dispersion with mean and statistical difference was determined by ANOVA with Fisher's LSD *post hoc*.


Figure 5 - Liver analysis. H&E from groups (A) control, (B) vehicle and (C) CBD, in with dark arrows represent mononuclear infiltrate. (D) Quantification of histopathological score; ELISA of (E) CCL2, (F) CCL3, (G) CCL5, (H) TNF α , (I) IFN γ (J) IL-10; and Flow cytometry displaying (K) Total lymphocytes; (L) CD3⁺CD4⁺ cells; (M) CD3⁺CD8⁺; (N)CD3⁺CD4⁺CD28⁺; (O) CD3⁺CD8⁺CD28⁺ and (P) CD4⁺CD25⁺FoxP3⁺ cells. * indicates $P < 0.05$ when compared to control group and # when $P < 0.05$ when compared to vehicle. Data were expressed in dispersion with mean and statistical difference was determined by ANOVA with Fisher's LSD *post hoc*; n=5 for all groups.

Figure 6 - Flow Cytometry of mice spleen and lymph nodes, seven days after disease induction and P815GFP⁺ cells transplant. (A) Percentage of P815⁺ cells in spleen; (B) Percentage of P815⁺ cells in lymph nodes. Absolute number of P815⁺ cells were represented in dispersion graphs next to Flow Cytometry shards; n=5 for all groups.

Figure 7 – Role of CB2 in the protective effect of CBD. (A) CBD in the presence of CB1 antagonist; (B) CBD in the presence of CB2 antagonist; (C) Treatment with CB1 antagonist without CBD; (D) Treatment with CB2 antagonist without CBD. (E) CD4 and CB2 mean integrated density, colocalization of CD4/CB2 and representative figures of groups (CD4 FITC, CB2 AlexaFluor 594 and DAPI); (F) CD8 and CB2 mean integrated density, colocalization of CD8/CB2 and representative figures of groups (CD8 PerCP, CB2 AlexaFluor 488 and DAPI); (G) FoxP3 and CB2 mean integrated density, colocalization of FoxP3/CB2 and representative figures of groups (FoxP3, CB2 AlexaFluor 488 and DAPI). Differences between groups were assessed with Log-rank (Mantel-Cox) test for $p < 0.05$; n=10/10/5/5 for survival and ANOVA with Fisher's LSD *post hoc*; n=5 for all groups in immunofluorescence.

Figure 8 - Schematic representation of our findings. CBD treatment, partially by CB2 receptor activation, increased the number of Tregs in the in the intestines and reduced cytokine/chemokine release. Together these factors led to the protection of target organs and the increase in mice survival.

Figure 1



JPET Fast Forward. Published on March 3, 2021. as DOI: 10.1124/jpet.120.000479
 This article has not been certified by peer review and is not intended to be used as a guide for clinical practice. The final version may differ from this version.

Figure 2




Figure 3





Figure 4




Figure 5





Figure 6

A



B




Figure 7





Figure 8



Supplemental Data

This are the supplemental figures from the manuscript number **MS ID#: JPET/2019/263699**

The Journal of Pharmacology and Experimental Therapeutics (JPET)

Cannabidiol Enhances Intestinal CB2 Receptor Expression and Activation Increasing Regulatory T Cells and Reduces Murine Acute Graft-Versus-Host Disease without Interfering with The Graft-Versus-Leukemia Response

Bárbara Betônico Berg^{1,2}, Jaqueline Silva Soares¹, Isabela Ribeiro Paiva^{1,2}, Barbara Maximino Rezende³, Milene Alvarenga Rachid⁴, Stêfany Bruno de Assis Cau^{1,2}, Thiago Roberto Lima Romero^{1,2}, Vanessa Pinho⁵, Mauro Martins Teixeira^{2,6}, Marina Gomes Miranda e Castor^{1,2}.

1- Departamento de Farmacologia-ICB/UFMG; 2- Programa de Pós-graduação em Fisiologia e Farmacologia da UFMG; 3-Departamento de Enfermagem Básica da Escola de Enfermagem da UFMG; 4- Departamento de Patologia Geral do Instituto de Ciências Biológicas da UFMG. 5 -Departamento de Morfologia - CPDF-ICB/UFMG; 6- Departamento de Bioquímica e Imunologia, CPDF-ICB/UFMG.

Supplemental Figures

Supplemental Figure 1. Antibodies used in immunofluorescence. Information regarding antibodies used in immunofluorescence assay, their dilution and source.

Supplemental Figure 2. Flow cytometry analysis of spleen. (A) Mix 1 regards the analysis of cell surface markers, such as CD3, CD4, CD8 and the activation marker CD28. (B) Mix 2 includes CD4 and CD25 as cell surface markers, and the intracellular FoxP3 for the characterization of Tregs.

Supplemental Figure 3. Flow cytometry analysis of small intestine. (A) Mix 1 comprehends CD3, CD4, CD8 and CD28, all cellular surface markers. (B) Mix 2 includes CD4, CD25 and FoxP3 in order to characterize T regulatory lymphocytes.

Supplemental Figure 4. Flow cytometry analysis of liver. (A) Mix 1 included CD3, CD4 and CD8 for the characterization of local lymphocytes, and CD28 as an activation marker. (B) Mix 2 regards T regs and was composed of CD4, CD25 and FoxP3 markers.

Supplemental Figure 5. Immunofluorescence of CD4/CB2 in small intestine. CD4 marker is stained with FITC (green arrow) and CB2 receptor with AlexaFluor594 (red arrow). In yellow it is possible to perceive colocalization of these markers (yellow arrow). For the staining of cell nuclei DAPI was used (blue marker). The last column displays a zoomed detailed part of the Merge image.

Supplemental Figure 6. Immunofluorescence of FoxP3/CB2 in small intestine. FoxP3 marker is stained with PE (red arrow) and CB2 receptor with AlexaFluor488 (green arrow). In yellow it is possible to perceive colocalization of these markers (yellow arrow). For the staining of cell nuclei DAPI was used (blue marker). The last column displays a zoomed detailed part of the Merge image.

Supplemental Figure 7. Immunofluorescence of CD8/CB2 in small intestine. CD8 marker is stained with PerCP (red arrow) and CB2 receptor with AlexaFluor488 (green arrow). In yellow it is possible to perceive colocalization of these markers (yellow arrow). For the staining of cell nuclei DAPI was used (blue marker). The last column displays a zoomed detailed part of the Merge image.

Supplemental Figure 8. Intravital analysis after GVHD was induced in Balb/c mice using C57BL/6J GFP+ mice as donors. At day 7 after transplant, mice were anesthetized intraperitoneally with 15 mg/Kg of xylazine and 80mg/Kg of Ketamine diluted in PBS autoclaved, and the mesentery exposed in a perfusion system containing PBS (pH 7.4) at 37° C. Only, 30 minutes before intravital assay, mice that received C57BL/6J GFP+ splenocytes were treated with 200µL of CBD vehicle (5% of Tween 80) or CBD 30 mg/kg. An intravital confocal microscope (Nikon, ECLIPSE 50i, 20x *objective lens*) was used to examine the mesenteric microcirculation. The images were recorded for playback analysis using Fiji-ImageJ with *plugin* NIS Elements-Nikon Imaging software (NIS ELEMENTS-NIKON). Intestinal venules ($\pm 40 \mu\text{m}$) were selected and the number of rolling and adherent leukocytes determined offline during video playback analysis. Rolling leukocytes were defined as those cells moving at velocity less than that of erythrocytes within a given vessel. The flux of rolling cells was measured as the number of rolling cells passing by a given point in the venule per minute. A leukocyte was adherent if it remained stationary for at least 30s, and total leukocyte adhesion was quantified as the number of cells in the intravascular space within area of 100 μm . Number of rolling cells per minute and number of adherent cells per 100um is presented as the mean \pm SEM (n= 6-8). * for P<0.05 when compared to the vehicle and CBD treated group.


Supplemental Figure 1. Antibodies used in immunofluorescence.

Figure S1

<i>Primary</i>				
<i>Antibody</i>	<i>Species</i>	<i>Source</i>	<i>Catalog Number</i>	<i>Dilution</i>
<i>CB2</i>	goat	Santa Cruz	(M-15): sc-10076	1:300
<i>CD4 FITC</i>	rat	BD Pharmingen™	553730	1:200
<i>CD8 PerCP</i>	rat	BD Pharmingen™	553036	1:200
<i>FoxP3 PE</i>	rat	eBioscience	12-5773-82	1:200
<i>Secondary</i>				
<i>AlexaFluor 488</i>	donkey anti-goat	Invitrogen - ThermoFischer	A11055	1:500
<i>AlexaFluor 594</i>	donkey anti-goat	Invitrogen - ThermoFischer	A11058	1:500


Supplemental Figure 2. Flow cytometry analysis of spleen.

Figure S2




Supplemental Figure 3. Flow cytometry analysis of small intestine.

Figure S3




Supplemental Figure 4. Flow cytometry analysis of liver

Figure S4




Supplemental Figure 5. Immunofluorescence of CD4/CB2 in small intestine.


Figure S5



Supplemental Figure 6. Immunofluorescence of FoxP3/CB2 in small intestine.



Supplemental Figure 7. Immunofluorescence of CD8/CB2 in small intestine.



Supplemental Figure 8. Intravital analysis after GVHD was induced in Balb/c mice using C57BL/6J GFP+ mice as donors.

Figure S8

